Bcl-2 inhibitors: small molecules with a big impact on cancer therapy
Top Cited Papers
Open Access
- 19 September 2008
- journal article
- review article
- Published by Springer Science and Business Media LLC in Cell Death & Differentiation
- Vol. 16 (3), 360-367
- https://doi.org/10.1038/cdd.2008.137
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- BH3 Mimetic ABT-737 Potentiates TRAIL-Mediated Apoptotic Signaling by Unsequestering Bim and Bak in Human Pancreatic Cancer CellsCancer Research, 2008
- Bcl-x L induces Drp1-dependent synapse formation in cultured hippocampal neuronsProceedings of the National Academy of Sciences of the United States of America, 2008
- The BCL-2 protein family: opposing activities that mediate cell deathNature Reviews Molecular Cell Biology, 2008
- Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosisProceedings of the National Academy of Sciences of the United States of America, 2007
- Pyrogallol-Based Molecules as Potent Inhibitors of the Antiapoptotic Bcl-2 ProteinsJournal of Medicinal Chemistry, 2007
- The Bcl-2 apoptotic switch in cancer development and therapyOncogene, 2007
- The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralizedCancer Cell, 2006
- Cell Death: Critical Control PointsCell, 2004
- Development of a Potent Bcl-xLAntagonist Based on α-Helix MimicryJournal of the American Chemical Society, 2002
- The Hallmarks of CancerCell, 2000